DDX11L2

Across TCGA pan-cancer cohorts, DDX11L2 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of DDX11L2’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where DDX11L2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types DDX11L2 is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

LIHC, KICH, and STAD are the cancer types where DDX11L2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DDX11L2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	+0.650	<.001	7	view →
KICH	All	All	−0.897	.001	5	view →
STAD	All	All	+0.566	.007	4	view →
CHOL	All	All	+1.558	<.001	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

DDX11L2–LIHC

Open the LIHC breakdown →